Search - tctmd.com

Displaying 21 - 40 of 48

Sort: Relevancy | Date

News Daily News

FDA Approval of Cangrelor Expands Antiplatelet Options for PCI

Todd Neale

June 29, 2015

News Daily News

Un Panel de la FDA Avala Cangrelor para ser Utilizado en PCI

Todd Neale

April 29, 2015

News Daily News

FDA Panel Backs Cangrelor for Use in PCI

Todd Neale

April 29, 2015

News Daily News

Study Quantifies Costs Arising From Thrombotic Events During PCI for NSTE-ACS

Caitlin E. Cox

April 09, 2015

Presentation TCT 2014

TCT 482: Effect of Cangrelor on Ischemic Endpoints: Further Analyses From CHAMPION PHOENIX

Presenter: John M. Lasala, Stuart J. Pocock, Deepak L. Bhatt

September 16, 2014

Presentation TCT 2014

Effect of Cangrelor on Ischemic Endpoints: Further Analyses from CHAMPION PHOENIX

Presenter: Deepak Bhatt

September 16, 2014

Presentation TCT 2014

YES: CHAMPION PHOENIX was Convincing!

Presenter: Deepak L. Bhatt

September 14, 2014

News Daily News

BRAVE 4: Prasugrel Plus Bivalirudin Fails to Mitigate Stent Thrombosis in STEMI Patients

May 14, 2014

News Conference News ACC 2014

CHAMPION PHOENIX Analysis: Cangrelor Reduces Early Stent Thrombosis, Suggesting Mortality Benefit

April 02, 2014

Presentation ACC 2014

Incidence and Impact of Stent Thrombosis During Percutaneous Coronary Intervention: Comparison of Cangrelor and Clopidogrel from the CHAMPION PHOENIX Trial

Presenter: Philippe Généreux

March 30, 2014

News Industry News

ANTI-CLOTTING AGENT HELPS REDUCE THE INCIDENCE AND IMPACT OF STENT THROMBOSIS DURING PERCUTANEOUS CORONARY INTERVENTION

March 27, 2014

News Daily News

Un Panel de la FDA Rechaza el Cangrelor para las Indicaciones PCI y Terapia Puente

Yael L. Maxwell

February 13, 2014

News Daily News

FDA Panel Rejects Cangrelor for Both PCI, Bridging Indications

Yael L. Maxwell

February 13, 2014

Presentation TCT 2013

Pro Position: The Data - Phoenix and Meta-Analysis of the Champion Clinical Trial Program!

Presenter: Philippe Gabriel Steg

October 31, 2013

Presentation TCT 2013

CHAMPION PHOENIX and CHAMPION Program Meta-Analysis

Presenter: Philippe Gabriel Steg

October 31, 2013

News Conference News TCT 2013

Intraprocedural ST Predicts Adverse Short-Term Events

October 29, 2013

Presentation TCT 2013

CHAMPION PHOENIX IPST: Implications of Intraprocedural Stent Thrombosis During PCI from a Prospective, Randomized Trial of a Potent Intravenous ADP Antagonist vs. a Standard Ora...

Presenter: Philippe Généreux

October 28, 2013

News Industry News

Anti-Clotting Agent Helps Reduce the Risk of Intraprocedural Events during Percutaneous Coronary Intervention

October 28, 2013

News Conference News ESC 2013

CHAMPION: Cangrelor Bests Clopidogrel in PCI Patients in Large Meta-analysis

Yael L. Maxwell

September 03, 2013

News Industry News

FDA Accepts the Filing of The Medicines Company's New Drug Application for Intravenous Antiplatelet Agent Cangrelor

July 01, 2013

Advertisement

FDA Approval of Cangrelor Expands Antiplatelet Options for PCI

Un Panel de la FDA Avala Cangrelor para ser Utilizado en PCI

FDA Panel Backs Cangrelor for Use in PCI

Study Quantifies Costs Arising From Thrombotic Events During PCI for NSTE-ACS

TCT 482: Effect of Cangrelor on Ischemic Endpoints: Further Analyses From CHAMPION PHOENIX

Effect of Cangrelor on Ischemic Endpoints: Further Analyses from CHAMPION PHOENIX

YES: CHAMPION PHOENIX was Convincing!

BRAVE 4: Prasugrel Plus Bivalirudin Fails to Mitigate Stent Thrombosis in STEMI Patients

CHAMPION PHOENIX Analysis: Cangrelor Reduces Early Stent Thrombosis, Suggesting Mortality Benefit

Incidence and Impact of Stent Thrombosis During Percutaneous Coronary Intervention: Comparison of Cangrelor and Clopidogrel from the CHAMPION PHOENIX Trial

ANTI-CLOTTING AGENT HELPS REDUCE THE INCIDENCE AND IMPACT OF STENT THROMBOSIS DURING PERCUTANEOUS CORONARY INTERVENTION

Un Panel de la FDA Rechaza el Cangrelor para las Indicaciones PCI y Terapia Puente

FDA Panel Rejects Cangrelor for Both PCI, Bridging Indications

Pro Position: The Data - Phoenix and Meta-Analysis of the Champion Clinical Trial Program!

CHAMPION PHOENIX and CHAMPION Program Meta-Analysis

Intraprocedural ST Predicts Adverse Short-Term Events

CHAMPION PHOENIX IPST: Implications of Intraprocedural Stent Thrombosis During PCI from a Prospective, Randomized Trial of a Potent Intravenous ADP Antagonist vs. a Standard Ora...

Anti-Clotting Agent Helps Reduce the Risk of Intraprocedural Events during Percutaneous Coronary Intervention

CHAMPION: Cangrelor Bests Clopidogrel in PCI Patients in Large Meta-analysis

FDA Accepts the Filing of The Medicines Company's New Drug Application for Intravenous Antiplatelet Agent Cangrelor

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content